Rate My Professor Anita Grigoriadis

Professor Anita Grigoriadis is Professor of Molecular and Digital Pathology in the School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine at King’s College London. She holds leadership positions as Head of the Comprehensive Cancer Centre, interim Joint Head of the School of Cancer & Pharmaceutical Sciences, head of the Cancer Bioinformatics group, and group lead of the Spatial Biology Network at Guy’s Cancer Centre. Additionally, she is an Executive Committee Member and Training Lead of the CRUK City of London Centre and co-leads the Spatial Biology Facility. Grigoriadis joined King’s College London in 2008 after working at the Ludwig Institute for Cancer Research, where she trained as a cancer biologist, and holding a visiting position at the Breakthrough Breast Cancer Centre at the Institute of Cancer Research. She established the Cancer Bioinformatics team in 2013. Her academic qualifications include an MSc in Bioinformatics with Systems Biology from University College London (2008), a PhD in Transcriptional regulation of p21 during senescence from the University of Salzburg (1997), and an MSc in Natural Science focused on isolation of genes in neuroblastoma from the University of Vienna (1993).

Grigoriadis’s research integrates computational and experimental approaches in translational cancer research, with a primary focus on breast cancer, including triple-negative breast cancer. Her group investigates molecular and morphological determinants at primary tumour sites and in draining lymph nodes, tumour-immune interplay, genomic instability, and systemic immune responses influencing treatment outcomes. She applies AI-powered methods to analyse large-scale data from digitised whole slide images, spatial transcriptomics, and multi-omics for early cancer detection. Key contributions include developing the GRAPE repository of over 1,500 lymph node images from breast cancer patients and the OASIS databank of normal breast tissue images for risk assessment in high-risk groups such as BRCA1/2 carriers. She co-leads the PharosAI national platform for AI model training on NHS and biobank data, securing £18.9 million in government funding in 2025. Selected publications are “An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer” (2026, NPJ Precision Oncology), “An Fc-Engineered Glycomodified Antibody Supports Pro-inflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer” (2025, Cancer Research), and “Issues and missed opportunities in lymph node assessment post neoadjuvant chemotherapy” (2025, Journal of Pathology). She serves as Editor for Cell Reports Medicine since 2021.